Osi Pharms Drug Patent Portfolio

Osi Pharms owns 1 orange book drug protected by 8 US patents Given below is the list of Osi Pharms's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6900221 Stable polymorph on N-(3-ethynylphenyl)-6, 7-bis (2methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof 09 May, 2021 Expired
US7087613 Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride 09 May, 2021 Expired
US6900221 Stable polymorph on N-(3-ethynylphenyl)-6, 7-bis (2methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof 09 Nov, 2020 Expired
US7087613 Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride 09 Nov, 2020 Expired
US5747498 Alkynyl and azido-substituted 4-anilinoquinazolines 08 May, 2019 Expired
USRE41065 Alkynl and azido-substituted 4-anilinoquinazolines 08 May, 2019 Expired
US5747498 Alkynyl and azido-substituted 4-anilinoquinazolines 08 Nov, 2018 Expired
USRE41065 Alkynl and azido-substituted 4-anilinoquinazolines 08 Nov, 2018 Expired


Given below is the list of recent legal activities going on the following drug patents of Osi Pharms.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 08 Feb, 2018 US7087613
Recordation of Patent Grant Mailed 08 Aug, 2006 US7087613
Patent Issue Date Used in PTA Calculation 08 Aug, 2006 US7087613
Issue Notification Mailed 19 Jul, 2006 US7087613
Application Is Considered Ready for Issue 05 Jul, 2006 US7087613
Dispatch to FDC 05 Jul, 2006 US7087613
Issue Fee Payment Verified 07 Jun, 2006 US7087613
Issue Fee Payment Received 07 Jun, 2006 US7087613
Mail Formal Drawings Required 09 Mar, 2006 US7087613
Mail Notice of Allowance 09 Mar, 2006 US7087613
Correction - Drawing NOT Required 09 Mar, 2006 US7087613
Notice of Allowance Data Verification Completed 02 Mar, 2006 US7087613
Formal Drawings Required 02 Mar, 2006 US7087613
PARALEGAL OR ELECTRONIC TERMINAL DISCLAIMER APPROVED 18 Feb, 2006 US7087613
Date Forwarded to Examiner 16 Feb, 2006 US7087613


Osi Pharms's Drug Patent Litigations

Osi Pharms's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jun 28, 2016, against patent number US6900221. The petitioner Apotex, Inc., challenged the validity of this patent, with OSI Pharmaceuticals, LLC as the respondent. Click below to track the latest information on how companies are challenging Osi Pharms's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US6900221 June, 2016 FWD Entered
(08 Jan, 2018)
OSI Pharmaceuticals, LLC Apotex, Inc.


Osi Pharms's Family Patents


Family Patents



Osi Pharms Drug List

Given below is the complete list of Osi Pharms's drugs and the patents protecting them.


1. Tarceva

Tarceva is protected by 8 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6900221
(Pediatric)
Stable polymorph on N-(3-ethynylphenyl)-6, 7-bis (2methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof 09 May, 2021
(3 years ago)
Expired
US7087613
(Pediatric)
Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride 09 May, 2021
(3 years ago)
Expired
US6900221 Stable polymorph on N-(3-ethynylphenyl)-6, 7-bis (2methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof 09 Nov, 2020
(3 years ago)
Expired
US7087613 Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride 09 Nov, 2020
(3 years ago)
Expired
US5747498
(Pediatric)
Alkynyl and azido-substituted 4-anilinoquinazolines 08 May, 2019
(5 years ago)
Expired
USRE41065
(Pediatric)
Alkynl and azido-substituted 4-anilinoquinazolines 08 May, 2019
(5 years ago)
Expired
US5747498 Alkynyl and azido-substituted 4-anilinoquinazolines 08 Nov, 2018
(5 years ago)
Expired
USRE41065 Alkynl and azido-substituted 4-anilinoquinazolines 08 Nov, 2018
(5 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tarceva's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List